Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/04/2003US6528653 Thienopyrrolidinones
03/04/2003US6528619 Cyclic peptide binding inhibitors; structural formulas; use drugs for diseases mediated by urokinase and receptor; tumors; inflammation; angiogenesis
03/04/2003US6528540 Administering by injection
03/04/2003US6528538 Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharamaceutical compositions and preparation process
03/04/2003US6528535 Bicyclic inhibitors of protein farnesyl transferase
03/04/2003US6528533 Treating or preventing neuronal damage associated with neurological diseases; hydrazide based compounds containing the group -N-N-CO-X- where X is C,O,S,or N
03/04/2003US6528528 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
03/04/2003US6528526 Inhibition of cell proliferation and/or cell matrix production and/or cell movement (chemotaxis) and/or T cell activation and proliferation
03/04/2003US6528524 Treating the multiple drug resistance, arrhythmia, spasms and malaria; reacting hydrochloric acid with cinchonine or to cinchonine monohydrochloride in form cinchonine dihydrochloride; high purity
03/04/2003US6528522 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
03/04/2003US6528520 Method of treating the syndrome of coronary heart disease risk factors in humans
03/04/2003US6528512 Cytokine specific binding protein;
03/04/2003US6528511 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528508 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli
03/04/2003US6528497 Anticoagulant and antithrombotic like heparin; hexadeca saccharides of three distinct sequences: a sulphated penta saccharide sequence DEFGH, a non-sulphated heptasaccharide sequence Z(MN)3 and a sulphated tetrasaccharide sequence VWXY.
03/04/2003US6528294 To effect protein phosphorylation; for use in diagnosis and therapy
03/04/2003US6528039 Low density microspheres and their use as contrast agents for computed tomography and in other applications
03/03/2003WO2002020496A1 2-guanidino-4-aryl-quinazoline
03/03/2003CA2421222A1 2-guanidino-4-aryl-quinazoline
02/2003
02/28/2003WO2002020009A1 Medicinal compositions
02/28/2003WO2002017913A1 Medicinal compositions for preventing or treating heart failure
02/28/2003CA2420951A1 Medicinal compositions
02/28/2003CA2420844A1 Medicinal compositions for preventing or treating heart failure
02/28/2003CA2399567A1 Crystalline material
02/27/2003WO2003016567A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
02/27/2003WO2003016563A2 Novel molecular target for neurotoxicity
02/27/2003WO2003016549A2 Nucleic-acid associated proteins
02/27/2003WO2003016530A1 Novel protein and its dna
02/27/2003WO2003016528A2 Oligonucleotide compositions and their use to induce apoptosis
02/27/2003WO2003016506A2 Secreted proteins
02/27/2003WO2003016493A2 Transporters and ion channels
02/27/2003WO2003016351A2 N - cam related compounds modulating cell groth
02/27/2003WO2003016341A2 Regulation of iron uptake
02/27/2003WO2003016314A1 1-alkyl 0r 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
02/27/2003WO2003016302A1 Diamine derivatives
02/27/2003WO2003016291A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
02/27/2003WO2003016288A1 Fxr nr1h4 nuclear receptor binding compounds
02/27/2003WO2003016279A1 Fused-polycyclic compounds
02/27/2003WO2003016270A2 Selective estrogen receptor modulators
02/27/2003WO2003016269A1 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
02/27/2003WO2003016265A1 Cyclic compound and ppar agonist
02/27/2003WO2003016248A2 Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
02/27/2003WO2003015831A1 Gas microsphere liposome composites
02/27/2003WO2003015820A1 GnRH AGONIST COMBINATION DRUGS
02/27/2003WO2003015819A1 Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
02/27/2003WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003WO2003015794A1 Methods and compositions for treating apoptosis associated disorders
02/27/2003WO2003015791A1 Phophylactic and therapeutic use of hydroxysteroids
02/27/2003WO2003015785A1 2h-phthalazin-1-ones and methods for use thereof
02/27/2003WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
02/27/2003WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
02/27/2003WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
02/27/2003WO2003015772A1 Inhibitors of polyq-aggregation
02/27/2003WO2003015770A1 Novel combination
02/27/2003WO2003015769A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments
02/27/2003WO2003015765A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
02/27/2003WO2003015762A1 Remedial agent for cardiac failure
02/27/2003WO2003015761A1 Selective estrogen receptor modulators
02/27/2003WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
02/27/2003WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
02/27/2003WO2003015717A2 Tyrosine kinase inhibitors
02/27/2003WO2003015704A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
02/27/2003WO2003015695A2 Canine cardiac diet
02/27/2003WO2003015690A2 Method for treating primary insomnia
02/27/2003WO2003015516A1 Compositions and methods for treatment of mitochondrial diseases
02/27/2003WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms
02/27/2003WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies
02/27/2003WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes
02/27/2003WO2002100862A3 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
02/27/2003WO2002094180A3 Pharmaceutically active isoindoline derivatives
02/27/2003WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors
02/27/2003WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists
02/27/2003WO2002089749A3 Arylsulfonamide ethers, and methods of use thereof
02/27/2003WO2002089740A3 Sulfonamides
02/27/2003WO2002087472A8 Stent-based delivery of statins to prevent restenosis
02/27/2003WO2002083864A3 Methods and reagents for cell transplantation
02/27/2003WO2002079149A3 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
02/27/2003WO2002066420A3 Tryptase inhibitors
02/27/2003WO2002064590A3 Carboline derivatives
02/27/2003WO2002061040A3 Gene delivery formulations and methods for treatment of ischemic conditions
02/27/2003WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
02/27/2003WO2002042436A3 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
02/27/2003WO2002038157A3 Inhibitors of thromboxane formation and action
02/27/2003WO2002028865A3 Condensed pyridoindole derivatives
02/27/2003WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
02/27/2003WO2002022111A3 Combination of lipoic acids and conjugated acids for treating diabetic disorders
02/27/2003WO2002020768A3 Caveolin peptides and their use as therapeutics
02/27/2003WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
02/27/2003WO2002000691A3 Polynucleotides and polypeptides encoded thereby
02/27/2003WO2001098481A3 Renal regulatory elements and methods of use thereof
02/27/2003WO2001098471A3 Human phosphodiesterases
02/27/2003WO2001098267A8 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
02/27/2003WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
02/27/2003US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection
02/27/2003US20030040631 As chemical intermediates used for the preparation of S-alpha-ethyl-2-oxo-1-pyrrolidine acetamide
02/27/2003US20030040625 For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia
02/27/2003US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof
02/27/2003US20030040541 Administering bismuth subgallate to inhibit the production of nitric oxide synthases (NOS)
1 ... 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 ... 1595